Accumulating evidence for statins in primary prevention

JAMA

Volumn 310, Issue 22, 2013, Pages 2405-2406

  Robinson, Jennifer G ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; ROSUVASTATIN;

ATHEROSCLEROSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL DECISION MAKING; MYOPATHY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; CARDIOVASCULAR DISEASES;

CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PRIMARY PREVENTION;

EID: 84889833385     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.281355     Document Type: Editorial

References (16)

1. Mihaylova B, Emberson J, Blackwell L, et al Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
2. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1(1):CD004816. doi:10.1002/14651858.CD14004816.pub14651855.
3. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;(1):CD004816. doi:10.1002/14651858.CD004816.pub4(1).
4. Taylor FC, Huffman M, Ebrahim S. Statin therapy for primary prevention of cardiovascular disease[published online November 25, 2013]. JAMA. doi:10.1001/jama.2013.281348.
5. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735-742.
6. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults [published online November 12, 2013]. Circulation. 2013. doi:10.1161/01.cir.0000437738.63853.7a.
7. Baigent C, Blackwell L, Emberson J, et al Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681.
8. Grundy SM, Cleeman JI, Merz CN, et al Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004;44(3):720-732.
9. Downs JR, Clearfield M, Weis S, et al; for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622.
10. Nakamura H, Arakawa K, Itakura H, et al MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial. Lancet. 2006;368(9542):1155-1163.
11. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
12. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556-2564.
13. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565-571.
14. Heart Protection Study Collaborative Group. Statin cost-effectiveness in the United States for people at different vascular risk levels. Circ Cardiovasc Qual Outcomes. 2009;2(2):65-72.
15. Grabowski DC, Lakdawalla DN, Goldman DP, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff (Millwood). 2012;31(10):2276-2285.
16. Go AS, Mozaffarian D, Roger VL, et al American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.